• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    IDEX Reports Third Quarter Results

    10/29/25 7:00:00 AM ET
    $IEX
    Fluid Controls
    Industrials
    Get the next $IEX alert in real time by email

    Highlights

    (All comparisons are against the prior year period unless otherwise noted)

    • Record sales of $879 million increased 10% on a reported basis and 5% organically
    • Reported diluted EPS of $1.70 increased 8%, and adjusted diluted EPS of $2.03 increased 7%
    • Record orders of $880 million increased 13% on a reported basis and 7% organically
    • Narrowed full year EPS outlook
      • GAAP diluted EPS of $6.35 - $6.40
      • Adjusted diluted EPS of $7.86 - $7.91
    • Utilized $75 million for share repurchases in Q3 2025 and $175 million year-to-date
    • Increased share repurchase authorization to $1 billion

    IDEX Corporation (NYSE:IEX) today announced its financial results for the three-month period ended September 30, 2025.

    "Our IDEX teams executed well in the third quarter, delivering solid results in an uncertain macroeconomic environment. We are focused squarely on what we can control as we leverage our 8020 approach to drive momentum within our growth platforms. Our teams are effectively collaborating across businesses to support our fastest growing customers, and our results are strong evidence of this, positioning IDEX to deliver against targets for the second half of 2025," said Eric D. Ashleman, IDEX Corporation Chief Executive Officer and President.

    "We support our growth efforts with a balanced capital deployment strategy, prioritizing allocation towards the highest return areas. In the near-term, we expect to continue our focus on returning capital to shareholders as we optimize our growth platform playbook and execute complementary bolt-on acquisitions. As we continue to execute our growth strategy, we are confident that we can achieve attractive growth and consistent value creation long-term."

    Outlook

    • Full Year 2025 GAAP diluted EPS narrowed to $6.35 - $6.40 (adjusted diluted EPS narrowed to $7.86 - $7.91), within prior guidance range
    • Full year 2025 organic sales growth of approximately 1% remains unchanged
    • Platform optimization and cost containment actions on pace to deliver $60+ million in full-year savings
    • On track to achieve at least 100% free cash flow conversion for full year 2025

    Consolidated Financial Results

     

    Three Months Ended September 30,

    (Dollars in millions, except per share amounts)

    2025

     

    2024

     

    Increase (Decrease)

    U.S. GAAP Results

     

     

     

     

     

    Orders

    $

    880.3

     

     

    $

    780.5

     

     

    $

    99.8

     

    Change in reported orders

     

     

     

     

     

    13

    %

    Net sales

     

    878.7

     

     

     

    798.2

     

     

     

    80.5

     

    Change in reported net sales

     

     

     

     

     

    10

    %

    Gross profit

     

    390.6

     

     

     

    353.9

     

     

     

    36.7

     

    Gross margin

     

    44.5

    %

     

     

    44.3

    %

     

    20 bps

    Net income attributable to IDEX

     

    127.8

     

     

     

    119.1

     

     

     

    8.7

     

    Net income margin

     

    14.5

    %

     

     

    14.9

    %

     

    (40) bps

    Diluted EPS attributable to IDEX

     

    1.70

     

     

     

    1.57

     

     

     

    0.13

     

    Cash flows from operating activities

     

    203.5

     

     

     

    205.3

     

     

     

    (1.8

    )

    Operating cash flow as a percent of net income

     

    159

    %

     

     

    172

    %

     

     

    NM

     

    Non-GAAP Results

     

     

     

     

     

    Change in organic orders*

     

     

     

     

     

    7

    %

    Change in organic sales*

     

     

     

     

     

    5

    %

    Adjusted gross profit*

     

    391.2

     

     

     

    356.0

     

     

     

    35.2

     

    Adjusted gross margin*

     

    44.5

    %

     

     

    44.6

    %

     

    (10) bps

    Adjusted net income attributable to IDEX*

     

    152.8

     

     

     

    144.1

     

     

     

    8.7

     

    Adjusted EBITDA*

     

    239.8

     

     

     

    214.3

     

     

     

    25.5

     

    Adjusted EBITDA margin*

     

    27.3

    %

     

     

    26.9

    %

     

    40 bps

    Adjusted diluted EPS attributable to IDEX*

     

    2.03

     

     

     

    1.90

     

     

     

    0.13

     

    Free cash flow*

     

    188.7

     

     

     

    191.6

     

     

     

    (2.9

    )

    Free cash flow conversion*

     

    123

    %

     

     

    133

    %

     

     

    NM

     

    NM – Not Meaningful

    *These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled "Non-GAAP Measures of Financial Performance" and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release.

    • Net sales increased largely due to the impact of the Mott Corporation ("Mott") acquisition completed in September 2024. Organic sales increased due to positive price across our businesses. Higher volumes in our Health & Science Technologies ("HST") and Fluid & Metering Technologies ("FMT") segments were mostly offset by lower volumes in our Fire & Safety/Diversified Products ("FSDP") segment.
    • Gross margin was relatively flat due to operational productivity improvements and lower fair value inventory step-up charges, partially offset by unfavorable mix and the impact of acquisitions. Platform optimization savings resulting from restructuring actions as well as other cost containment actions taken during 2025 mitigated increases in other employee-related costs. Adjusted gross margin was relatively flat as it excludes the benefit of lower fair value inventory step-up charges.
    • Both Diluted EPS and Adjusted diluted EPS increased. Improved operational results, driven by positive price/cost and net favorable operational productivity, were offset by higher interest expense due to higher debt outstanding throughout the current year period related to the 2024 acquisition of Mott, higher depreciation expense and a higher effective tax rate resulting primarily from a lower benefit from certain foreign sourced income as a result of newly enacted legislation. GAAP Diluted EPS also reflects higher amortization expense from the acquisition of Mott largely offset by lower fair value inventory step-up charges and lower restructuring and asset impairment expense, all of which were excluded from Adjusted diluted EPS.
    • Cash flows from operating activities and free cash flow continue to be strong and were both relatively flat compared to the prior year period. Higher earnings and lower cash tax payments were offset by timing of shipments and higher interest payments on senior notes to fund the acquisition of Mott.

    Segment Financial Results

     

    Three Months Ended September 30,(1)

    (Dollars in millions)

    2025

     

    2024

     

    Increase (Decrease)

    Health & Science Technologies

     

     

     

     

     

    Net sales

    $

    381.0

     

     

    $

    311.0

     

     

    $

    70.0

     

    Change in reported net sales

     

     

     

     

     

    22

    %

    Change in organic sales*

     

     

     

     

     

    10

    %

    Adjusted EBITDA(2)

     

    105.4

     

     

     

    82.6

     

     

     

    22.8

     

    Adjusted EBITDA margin

     

    27.7

    %

     

     

    26.5

    %

     

    120 bps

    Fluid & Metering Technologies

     

     

     

     

     

    Net sales

    $

    317.1

     

     

    $

    300.8

     

     

    $

    16.3

     

    Change in reported net sales

     

     

     

     

     

    5

    %

    Change in organic sales*

     

     

     

     

     

    4

    %

    Adjusted EBITDA(2)

     

    106.8

     

     

     

    98.5

     

     

     

    8.3

     

    Adjusted EBITDA margin

     

    33.7

    %

     

     

    32.8

    %

     

    90 bps

    Fire & Safety/Diversified Products

     

     

     

     

     

    Net sales

    $

    181.9

     

     

    $

    188.0

     

     

    $

    (6.1

    )

    Change in reported net sales

     

     

     

     

     

    (3

    %)

    Change in organic sales*

     

     

     

     

     

    (5

    %)

    Adjusted EBITDA(2)

     

    49.3

     

     

     

    54.7

     

     

     

    (5.4

    )

    Adjusted EBITDA margin

     

    27.1

    %

     

     

    29.1

    %

     

    (200) bps

    *These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled "Non-GAAP Measures of Financial Performance" and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release.

    (1) Three month data includes the results of the acquisition of Micro-LAM, Inc. ("Micro-LAM") (July 2025) and Mott (September 2024) both in the HST segment.

    (2) Segment Adjusted EBITDA excludes unallocated corporate costs which are included in Corporate and other.

    Health & Science Technologies Segment

    • Net sales for the third quarter 2025 increased 22% driven by the acquisition of Mott. Organic sales increased 10% due to favorable volumes driven by timing of progress made on large orders at Mott as well as higher volumes in our life sciences, pharmaceutical, space and defense, data center and semiconductor consumables businesses, partially offset by lower volumes in our semiconductor lithography and industrial businesses. Net sales also reflect positive price across the segment.
    • Adjusted EBITDA margin for the third quarter 2025 increased primarily due to volume leverage as well as net productivity improvements, including platform optimization savings and cost containment, and favorable price/cost, partially offset by acquisitions and unfavorable mix.

    Fluid & Metering Technologies Segment

    • Net sales for the third quarter 2025 increased 5%. Organic sales increased 4% primarily driven by positive price and slightly higher volumes as compared to the prior year period.
    • Adjusted EBITDA margin for the third quarter 2025 increased primarily due to positive price/cost as well as net productivity improvements, including platform optimization savings and cost containment.

    Fire & Safety/Diversified Products Segment

    • Net sales for the third quarter 2025 decreased 3%. Organic sales decreased 5% driven by lower volumes within our Fire and Safety and Dispensing businesses, partially offset by positive price.
    • Adjusted EBITDA margin for the third quarter 2025 decreased primarily due to volume deleverage, partially offset by price/cost. Operational productivity improvements, platform optimization savings and cost containment offset other higher employee-related costs.

    Corporate Costs

    Corporate costs included in consolidated Adjusted EBITDA were $21.7 million during the third quarter 2025, up slightly from $21.5 million during the same prior year period. Both periods benefited from variable compensation adjustments.

    Other Items

    • Repurchased 461,500 shares at a cost of $75.0 million
    • Completed the acquisition of Micro-LAM for cash consideration of $80.7 million

    Conference Call to be Broadcast over the Internet

    IDEX will broadcast its third quarter earnings conference call over the Internet on Wednesday, October 29, 2025 at 8:00 a.m. CT. Chief Executive Officer and President Eric Ashleman and Vice President, Corporate Development and Interim Chief Financial Officer Akhil Mahendra will discuss the Company's recent financial performance and respond to questions from the financial analyst community. IDEX invites interested investors to listen to the call and view the accompanying slide presentation, which will be available on its website at www.idexcorp.com and the slide presentation will also be available on that website after the call. Those who wish to participate should log on several minutes before the discussion begins. After clicking on the presentation icon, investors should follow the instructions to ensure their systems are set up to hear the event and view the presentation slides or download the correct applications at no charge. Investors will also be able to hear a replay of the call by dialing 877.709.8150 (or 201.689.8354 for international participants) using the ID #13748413.

    Forward-Looking Statements

    This news release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company's fourth quarter 2025 and full year 2025 outlook including expected organic sales, expected earnings per share, and expected adjusted earnings per share and the assumptions underlying these expectations, capital return strategy, anticipated future acquisition behavior and the anticipated benefits and performance of the Company's recent or future acquisitions, resource and capital deployment and focus and organic and inorganic growth, the Company's ability to adapt to macroeconomic challenges, anticipated impacts of tariffs and global trade policies and changes in law, including the One, Big, Beautiful Bill Act, anticipated trends in end markets, including expectations regarding future order volumes and order patterns, anticipated growth initiatives and expansions, anticipated benefits and restructuring charges, including severance charges, related to the Company's organizational changes and the anticipated benefits of the Company's productivity and cost containment efforts and are indicated by words or phrases such as "anticipates," "estimates," "plans," "guidance," "expects," "projects," "forecasts," "should," "could," "will," "likely to be," "management believes," "the Company believes," "the Company intends" and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release.

    The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries; the impact of severe weather events, natural disasters and public health threats; economic and political consequences resulting from terrorist attacks and wars; the Company's ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; cybersecurity incidents; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in countries in which the Company operates; developments with respect to trade policy and existing, new or increased tariffs or other similar measures; changes to applicable laws and regulations, including tax laws; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters.

    Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the "Risk Factors" section included in the Company's most recent annual report on Form 10-K and the Company's subsequent quarterly reports filed with the United States Securities and Exchange Commission ("SEC") and the other risks discussed in the Company's filings with the SEC. The forward-looking statements included here are only made as of the date of this news release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

    About IDEX

    IDEX Corporation (NYSE:IEX) designs and builds engineered products and mission-critical components that make everyday life better. IDEX precision components help craft the microchip powering your electronics, treat water so it is safe to drink, and protect communities and the environment from sewer overflows. Our optics enable global broadband satellite communications, and our pumps move challenging fluids that range from hot, to viscous, to caustic. IDEX components assist healthcare professionals in saving lives as part of many leading diagnostic machines, including DNA sequencers that help doctors personalize treatment. And our fire and rescue tools, including the industry-leading Hurst Jaws of Life®, are trusted by rescue workers around the world. These are just some of the thousands of products that help IDEX live its purpose – Trusted Solutions, Improving Lives™. Founded in 1988 with three small, entrepreneurial manufacturing companies, IDEX now includes more than 50 diverse businesses around the world. With about 9,000 employees and manufacturing operations in more than 20 countries, IDEX is a diversified, high-performing, global company with approximately $3.3 billion in annual sales.

    For further information on IDEX Corporation and its business units, visit the company's website at www.idexcorp.com.

    (Financial reports follow)

    IDEX CORPORATION

    Condensed Consolidated Statements of Income

    (in millions, except per share amounts)

    (unaudited)

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2025

     

    2024

     

    2025

     

    2024

    Net sales

    $

    878.7

     

     

    $

    798.2

     

    $

    2,558.4

     

    $

    2,405.9

     

    Cost of sales

     

    488.1

     

     

     

    444.3

     

     

    1,406.7

     

     

    1,327.8

     

    Gross profit

     

    390.6

     

     

     

    353.9

     

     

    1,151.7

     

     

    1,078.1

     

    Selling, general and administrative expenses

     

    204.7

     

     

     

    182.9

     

     

    617.7

     

     

    560.8

     

    Restructuring expenses and asset impairments

     

    0.1

     

     

     

    3.0

     

     

    18.3

     

     

    5.4

     

    Operating income

     

    185.8

     

     

     

    168.0

     

     

    515.7

     

     

    511.9

     

    Gain on sale of business(1)

     

    —

     

     

     

    0.6

     

     

    —

     

     

    (4.0

    )

    Other (income) expense – net

     

    (1.2

    )

     

     

    2.7

     

     

    2.6

     

     

    —

     

    Interest expense – net

     

    16.5

     

     

     

    10.3

     

     

    48.2

     

     

    27.8

     

    Income before income taxes

     

    170.5

     

     

     

    154.4

     

     

    464.9

     

     

    488.1

     

    Provision for income taxes

     

    42.8

     

     

     

    35.5

     

     

    110.7

     

     

    106.7

     

    Net income

     

    127.7

     

     

     

    118.9

     

     

    354.2

     

     

    381.4

     

    Net loss attributable to noncontrolling interest

     

    0.1

     

     

     

    0.2

     

     

    0.7

     

     

    0.4

     

    Net income attributable to IDEX

    $

    127.8

     

     

    $

    119.1

     

    $

    354.9

     

    $

    381.8

     

     

     

     

     

     

     

     

     

    Earnings per Common Share:

     

     

     

     

     

     

     

    Basic earnings per common share attributable to IDEX

    $

    1.70

     

     

    $

    1.57

     

    $

    4.70

     

    $

    5.03

     

    Diluted earnings per common share attributable to IDEX

    $

    1.70

     

     

    $

    1.57

     

    $

    4.70

     

    $

    5.02

     

     

     

     

     

     

     

     

     

    Share Data:

     

     

     

     

     

     

     

    Basic weighted average common shares outstanding

     

    75.1

     

     

     

    75.7

     

     

    75.4

     

     

    75.7

     

    Diluted weighted average common shares outstanding

     

    75.2

     

     

     

    75.9

     

     

    75.5

     

     

    75.9

     

    (1)

    Activity recorded during the three months ended September 30, 2024 represents the finalization of the gain on the sale of Alfa Valvole, Srl resulting in a $0.6 million downward adjustment during the third quarter of 2024.

    IDEX CORPORATION

    Condensed Consolidated Balance Sheets

    (in millions)

    (unaudited)

     

    September 30, 2025

     

    December 31, 2024

    Assets

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    593.8

     

     

    $

    620.8

     

    Receivables – net

     

    500.2

     

     

     

    465.9

     

    Inventories – net

     

    495.1

     

     

     

    429.7

     

    Other current assets

     

    65.8

     

     

     

    76.3

     

    Total current assets

     

    1,654.9

     

     

     

    1,592.7

     

    Property, plant and equipment - net

     

    468.6

     

     

     

    460.4

     

    Goodwill

     

    3,408.8

     

     

     

    3,251.7

     

    Intangible assets - net

     

    1,281.5

     

     

     

    1,284.8

     

    Other noncurrent assets

     

    155.9

     

     

     

    155.7

     

    Total assets

    $

    6,969.7

     

     

    $

    6,745.3

     

     

     

     

     

    Liabilities and equity

     

     

     

    Current liabilities

     

     

     

    Trade accounts payable

    $

    208.1

     

     

    $

    197.8

     

    Accrued expenses

     

    302.0

     

     

     

    278.7

     

    Current portion of long-term borrowings

     

    0.7

     

     

     

    100.7

     

    Dividends payable

     

    53.2

     

     

     

    52.5

     

    Total current liabilities

     

    564.0

     

     

     

    629.7

     

    Long-term borrowings – net

     

    1,901.6

     

     

     

    1,859.5

     

    Deferred income taxes

     

    287.8

     

     

     

    267.2

     

    Other noncurrent liabilities

     

    206.2

     

     

     

    194.8

     

    Total liabilities

     

    2,959.6

     

     

     

    2,951.2

     

    Shareholders' equity

     

     

     

    Preferred stock

     

    —

     

     

     

    —

     

    Common stock

     

    0.9

     

     

     

    0.9

     

    Treasury stock

     

    (1,348.1

    )

     

     

    (1,170.3

    )

    Additional paid-in capital

     

    888.5

     

     

     

    864.8

     

    Retained earnings

     

    4,424.8

     

     

     

    4,230.2

     

    Accumulated other comprehensive income (loss)

     

    45.3

     

     

     

    (130.9

    )

    Total shareholders' equity

     

    4,011.4

     

     

     

    3,794.7

     

    Noncontrolling interest

     

    (1.3

    )

     

     

    (0.6

    )

    Total equity

     

    4,010.1

     

     

     

    3,794.1

     

    Total liabilities and equity

    $

    6,969.7

     

     

    $

    6,745.3

     

    IDEX CORPORATION

    Condensed Consolidated Statements of Cash Flows

    (in millions)

    (unaudited)

     

    Nine Months Ended September 30,

     

    2025

     

    2024

    Cash flows from operating activities

     

     

     

    Net income

    $

    354.2

     

     

    $

    381.4

     

    Adjustments to reconcile net income to net cash flows provided by operating activities:

     

     

     

    Gain on sale of business

     

    —

     

     

     

    (4.0

    )

    Asset impairments

     

    0.7

     

     

     

    —

     

    Depreciation

     

    56.5

     

     

     

    49.9

     

    Amortization of intangible assets

     

    96.5

     

     

     

    75.0

     

    Share-based compensation expense

     

    23.7

     

     

     

    20.9

     

    Deferred income taxes

     

    (1.0

    )

     

     

    0.4

     

    Changes in (net of the effect from acquisitions/divestitures and foreign currency translation):

     

     

     

    Receivables – net

     

    (20.2

    )

     

     

    (14.5

    )

    Inventories – net

     

    (49.4

    )

     

     

    (21.6

    )

    Other current assets

     

    (1.4

    )

     

     

    (4.6

    )

    Trade accounts payable

     

    (1.1

    )

     

     

    15.3

     

    Deferred revenue

     

    (1.1

    )

     

     

    (4.3

    )

    Accrued expenses

     

    10.4

     

     

     

    (0.5

    )

    Other – net

     

    3.1

     

     

     

    2.1

     

    Net cash flows provided by operating activities

     

    470.9

     

     

     

    495.5

     

    Cash flows from investing activities

     

     

     

    Capital expenditures

     

    (43.9

    )

     

     

    (49.6

    )

    Acquisition of business, net of cash acquired

     

    (76.5

    )

     

     

    (984.5

    )

    Proceeds from sale of business, net of cash remitted

     

    —

     

     

     

    45.1

     

    Other – net

     

    0.4

     

     

     

    (2.8

    )

    Net cash flows used in investing activities

     

    (120.0

    )

     

     

    (991.8

    )

    Cash flows from financing activities

     

     

     

    Borrowings under revolving credit facilities

     

    197.0

     

     

     

    279.3

     

    Proceeds from issuance of long-term borrowings

     

    —

     

     

     

    496.7

     

    Payment of long-term borrowings

     

    (100.0

    )

     

     

    (25.0

    )

    Payments under revolving credit facilities

     

    (185.8

    )

     

     

    —

     

    Cash dividends paid to shareholders

     

    (159.4

    )

     

     

    (153.0

    )

    (Payments) proceeds from share issuances, net of shares withheld for taxes

     

    (1.2

    )

     

     

    10.5

     

    Repurchases of common stock

     

    (175.0

    )

     

     

    —

     

    Other – net

     

    (0.5

    )

     

     

    (0.6

    )

    Net cash flows (used in) provided by financing activities

     

    (424.9

    )

     

     

    606.7

     

    Effect of exchange rate changes on cash and cash equivalents

     

    34.8

     

     

     

    6.6

     

    Net (decrease) increase in cash and cash equivalents and restricted cash

     

    (39.2

    )

     

     

    117.0

     

    Cash and cash equivalents and restricted cash at beginning of year(1)

     

    638.9

     

     

     

    534.3

     

    Cash and cash equivalents and restricted cash at end of period(1)

    $

    599.7

     

     

    $

    651.3

     

    (1)

    Includes $5.9 million of restricted cash at September 30, 2025 and $18.1 million at both September 30, 2024 and December 31, 2024. At September 30, 2025, $3.0 million of the restricted cash has been included in Other current assets and $2.9 million has been included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. At September 30, 2024 and December 31, 2024, $18.1 million was included in Other current assets in the Condensed Consolidated Balance Sheets. There was no restricted cash as of December 31, 2023.

    IDEX CORPORATION

    Company and Segment Financial Information

    (in millions)

    (unaudited)

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2025

     

    2024

     

    2025

     

    2024

    Net sales

     

     

     

     

     

     

     

    Health & Science Technologies

    $

    381.0

     

     

    $

    311.0

     

     

    $

    1,087.8

     

     

    $

    924.9

     

    Fluid & Metering Technologies

     

    317.1

     

     

     

    300.8

     

     

     

    918.5

     

     

     

    933.9

     

    Fire & Safety/Diversified Products

     

    181.9

     

     

     

    188.0

     

     

     

    557.7

     

     

     

    551.4

     

    Eliminations

     

    (1.3

    )

     

     

    (1.6

    )

     

     

    (5.6

    )

     

     

    (4.3

    )

    Total IDEX

    $

    878.7

     

     

    $

    798.2

     

     

    $

    2,558.4

     

     

    $

    2,405.9

     

    Depreciation

     

     

     

     

     

     

     

    Health & Science Technologies

    $

    11.9

     

     

    $

    10.6

     

     

    $

    35.5

     

     

    $

    29.5

     

    Fluid & Metering Technologies

     

    4.7

     

     

     

    4.3

     

     

     

    13.5

     

     

     

    12.9

     

    Fire & Safety/Diversified Products

     

    2.3

     

     

     

    2.2

     

     

     

    6.9

     

     

     

    6.7

     

    Corporate Office

     

    0.2

     

     

     

    0.3

     

     

     

    0.6

     

     

     

    0.8

     

    Total IDEX

    $

    19.1

     

     

    $

    17.4

     

     

    $

    56.5

     

     

    $

    49.9

     

    Amortization of intangible assets

     

     

     

     

     

     

     

    Health & Science Technologies

    $

    26.2

     

     

    $

    19.7

     

     

    $

    76.2

     

     

    $

    54.6

     

    Fluid & Metering Technologies

     

    5.5

     

     

     

    5.2

     

     

     

    16.2

     

     

     

    15.7

     

    Fire & Safety/Diversified Products

     

    1.3

     

     

     

    1.6

     

     

     

    4.1

     

     

     

    4.7

     

    Total IDEX

    $

    33.0

     

     

    $

    26.5

     

     

    $

    96.5

     

     

    $

    75.0

     

    Restructuring expenses and asset impairments

     

     

     

     

     

     

     

    Health & Science Technologies

    $

    —

     

     

    $

    1.7

     

     

    $

    12.1

     

     

    $

    3.3

     

    Fluid & Metering Technologies

     

    0.1

     

     

     

    1.0

     

     

     

    4.3

     

     

     

    1.6

     

    Fire & Safety/Diversified Products

     

    —

     

     

     

    0.1

     

     

     

    1.6

     

     

     

    0.2

     

    Corporate Office

     

    —

     

     

     

    0.2

     

     

     

    0.3

     

     

     

    0.3

     

    Total IDEX

    $

    0.1

     

     

    $

    3.0

     

     

    $

    18.3

     

     

    $

    5.4

     

    Non-GAAP Measures of Financial Performance

    The Company prepares its public financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP). The Company supplements certain GAAP financial performance metrics with non-GAAP financial performance metrics. Management believes these non-GAAP financial performance metrics provide investors with greater insight, transparency and a more comprehensive understanding of the financial information used by management in its financial and operational decision making because certain of these adjusted metrics exclude items not reflective of ongoing operations, as identified in the reconciliations below. Reconciliations of non-GAAP financial performance metrics to their most directly comparable GAAP financial performance metrics are defined and presented below and should not be considered a substitute for, nor superior to, the financial data prepared in accordance with GAAP. Due to rounding, numbers presented throughout this and other documents may not add up or recalculate precisely.

    All table footnotes can be found at the end of this Non-GAAP Measures section. There were no adjustments to GAAP financial performance metrics other than the items noted below.

    • Organic orders and organic sales are calculated as orders and Net sales excluding amounts from acquired or divested businesses during the first twelve months of ownership or prior to divestiture and excluding the impact of foreign currency translation.
    • Adjusted gross profit is calculated as Gross profit plus fair value inventory step-up charges.
    • Adjusted gross margin is calculated as adjusted gross profit divided by Net sales.
    • Adjusted net income attributable to IDEX is calculated as Net income attributable to IDEX plus fair value inventory step-up charges, plus Restructuring expenses and asset impairments, less the Gain on sale of a business, plus acquisition-related intangible asset amortization, all net of the statutory tax expense or benefit.
    • Adjusted diluted EPS attributable to IDEX is calculated as adjusted net income attributable to IDEX divided by the diluted weighted average shares outstanding.
    • Consolidated Adjusted EBITDA is calculated as consolidated earnings before interest expense - net, income taxes, depreciation and amortization, or consolidated EBITDA, less the Gain on sale of a business, plus fair value inventory step-up charges, plus Restructuring expenses and asset impairments.
    • Consolidated Adjusted EBITDA margin is calculated as Consolidated Adjusted EBITDA divided by Net sales.
    • Free cash flow is calculated as cash flows from operating activities less capital expenditures. Free cash flow conversion is calculated as free cash flow divided by adjusted net income attributable to IDEX.

    Table 1: Reconciliations of the Change in Net Sales to Organic Sales

     

    HST

     

    FMT

     

    FSDP

     

    IDEX

     

    Three Months Ended September 30, 2025

    Change in net sales

    22

    %

     

    5

    %

     

    (3

    %)

     

    10

    %

    Less:

     

     

     

     

     

     

     

    Net impact from acquisitions/divestitures(1)

    11

    %

     

    —

    %

     

    —

    %

     

    4

    %

    Impact from foreign currency(2)

    1

    %

     

    1

    %

     

    2

    %

     

    1

    %

    Change in organic net sales

    10

    %

     

    4

    %

     

    (5

    %)

     

    5

    %

     

     

     

     

     

     

     

     

     

    Nine Months Ended September 30, 2025

    Change in net sales

    18

    %

     

    (2

    %)

     

    1

    %

     

    6

    %

    Less:

     

     

     

     

     

     

     

    Net impact from acquisitions/divestitures(1)

    13

    %

     

    (1

    %)

     

    —

    %

     

    4

    %

    Impact from foreign currency(2)

    1

    %

     

    —

    %

     

    1

    %

     

    1

    %

    Change in organic sales

    4

    %

     

    (1

    %)

     

    —

    %

     

    1

    %

    Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (dollars in millions)

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2025

     

    2024

     

    2025

     

    2024

    Gross profit

    $

    390.6

     

     

    $

    353.9

     

     

    $

    1,151.7

     

     

    $

    1,078.1

     

    Fair value inventory step-up charges

     

    0.6

     

     

     

    2.1

     

     

     

    0.6

     

     

     

    4.6

     

    Adjusted gross profit

    $

    391.2

     

     

    $

    356.0

     

     

    $

    1,152.3

     

     

    $

    1,082.7

     

     

     

     

     

     

     

     

     

    Net sales

    $

    878.7

     

     

    $

    798.2

     

     

    $

    2,558.4

     

     

    $

    2,405.9

     

     

     

     

     

     

     

     

     

    Gross margin

     

    44.5

    %

     

     

    44.3

    %

     

     

    45.0

    %

     

     

    44.8

    %

    Adjusted gross margin

     

    44.5

    %

     

     

    44.6

    %

     

     

    45.0

    %

     

     

    45.0

    %

    Table 3: Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except per share amounts)

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2025

     

    2024

     

    2025

     

    2024

    Reported net income attributable to IDEX

    $

    127.8

     

     

    $

    119.1

     

     

    $

    354.9

     

     

    $

    381.8

     

    Fair value inventory step-up charges

     

    0.6

     

     

     

    2.1

     

     

     

    0.6

     

     

     

    4.6

     

    Tax impact on fair value inventory step-up charges

     

    (0.1

    )

     

     

    (0.5

    )

     

     

    (0.1

    )

     

     

    (1.0

    )

    Restructuring expenses and asset impairments(3)

     

    0.1

     

     

     

    3.0

     

     

     

    18.0

     

     

     

    5.4

     

    Tax impact on restructuring expenses and asset impairments

     

    (0.1

    )

     

     

    (0.7

    )

     

     

    (4.4

    )

     

     

    (1.3

    )

    Gain on sale of business

     

    —

     

     

     

    0.6

     

     

     

    —

     

     

     

    (4.0

    )

    Tax impact on gain of sale of business

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Acquisition-related intangible asset amortization

     

    33.0

     

     

     

    26.5

     

     

     

    96.5

     

     

     

    75.0

     

    Tax impact on acquisition-related intangible asset amortization

     

    (8.5

    )

     

     

    (6.0

    )

     

     

    (23.2

    )

     

     

    (17.1

    )

    Adjusted net income attributable to IDEX

    $

    152.8

     

     

    $

    144.1

     

     

    $

    442.3

     

     

    $

    443.4

     

     

     

     

     

     

     

     

     

    Reported diluted EPS attributable to IDEX

    $

    1.70

     

     

    $

    1.57

     

     

    $

    4.70

     

     

    $

    5.02

     

    Fair value inventory step-up charges

     

    0.01

     

     

     

    0.03

     

     

     

    0.01

     

     

     

    0.06

     

    Tax impact on fair value inventory step-up charges

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (0.01

    )

    Restructuring expenses and asset impairments(3)

     

    —

     

     

     

    0.04

     

     

     

    0.24

     

     

     

    0.07

     

    Tax impact on restructuring expenses and asset impairments

     

    —

     

     

     

    (0.01

    )

     

     

    (0.06

    )

     

     

    (0.02

    )

    Gain on sale of business

     

    —

     

     

     

    0.01

     

     

     

    —

     

     

     

    (0.05

    )

    Tax impact on gain of sale of business

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Acquisition-related intangible asset amortization

     

    0.43

     

     

     

    0.35

     

     

     

    1.27

     

     

     

    0.99

     

    Tax impact on acquisition-related intangible asset amortization

     

    (0.11

    )

     

     

    (0.09

    )

     

     

    (0.31

    )

     

     

    (0.22

    )

    Adjusted diluted EPS attributable to IDEX

    $

    2.03

     

     

    $

    1.90

     

     

    $

    5.85

     

     

    $

    5.84

     

     

     

     

     

     

     

     

     

    Diluted weighted average shares outstanding

     

    75.2

     

     

     

    75.9

     

     

     

    75.5

     

     

     

    75.9

     

    Table 4: Reconciliations of Net Income to Adjusted EBITDA (dollars in millions)

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2025

     

    2024

     

    2025

     

    2024

    Reported net income

    $

    127.7

     

     

    $

    118.9

     

     

    $

    354.2

     

     

    $

    381.4

     

    Provision for income taxes

     

    42.8

     

     

     

    35.5

     

     

     

    110.7

     

     

     

    106.7

     

    Interest expense - net

     

    16.5

     

     

     

    10.3

     

     

     

    48.2

     

     

     

    27.8

     

    Gain on sale of business

     

    —

     

     

     

    0.6

     

     

     

    —

     

     

     

    (4.0

    )

    Depreciation

     

    19.1

     

     

     

    17.4

     

     

     

    56.5

     

     

     

    49.9

     

    Amortization

     

    33.0

     

     

     

    26.5

     

     

     

    96.5

     

     

     

    75.0

     

    Fair value inventory step-up charges

     

    0.6

     

     

     

    2.1

     

     

     

    0.6

     

     

     

    4.6

     

    Restructuring expenses and asset impairments

     

    0.1

     

     

     

    3.0

     

     

     

    18.3

     

     

     

    5.4

     

    Adjusted EBITDA

    $

    239.8

     

     

    $

    214.3

     

     

    $

    685.0

     

     

    $

    646.8

     

     

     

     

     

     

     

     

     

    Adjusted EBITDA Components:

     

     

     

     

     

     

     

    HST

    $

    105.4

     

     

    $

    82.6

     

     

    $

    287.8

     

     

    $

    248.2

     

    FMT

     

    106.8

     

     

     

    98.5

     

     

     

    310.8

     

     

     

    311.6

     

    FSDP

     

    49.3

     

     

     

    54.7

     

     

     

    159.9

     

     

     

    159.9

     

    Corporate and other

     

    (21.7

    )

     

     

    (21.5

    )

     

     

    (73.5

    )

     

     

    (72.9

    )

    Total Adjusted EBITDA

    $

    239.8

     

     

    $

    214.3

     

     

    $

    685.0

     

     

    $

    646.8

     

     

     

     

     

     

     

     

     

    Net sales

    $

    878.7

     

     

    $

    798.2

     

     

    $

    2,558.4

     

     

    $

    2,405.9

     

     

     

     

     

     

     

     

     

    Net income margin

     

    14.5

    %

     

     

    14.9

    %

     

     

    13.8

    %

     

     

    15.9

    %

    Adjusted EBITDA margin

     

    27.3

    %

     

     

    26.9

    %

     

     

    26.8

    %

     

     

    26.9

    %

    Table 5: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (dollars in millions)

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2025

     

    2024

     

    2025

     

    2024

    Cash flows from operating activities

    $

    203.5

     

     

    $

    205.3

     

     

    $

    470.9

     

     

    $

    495.5

     

    Less: Capital expenditures

     

    14.8

     

     

     

    13.7

     

     

     

    43.9

     

     

     

    49.6

     

    Free cash flow

    $

    188.7

     

     

    $

    191.6

     

     

    $

    427.0

     

     

    $

    445.9

     

     

     

     

     

     

     

     

     

    Reported net income attributable to IDEX

    $

    127.8

     

     

    $

    119.1

     

     

    $

    354.9

     

     

    $

    381.8

     

    Adjusted net income attributable to IDEX

     

    152.8

     

     

     

    144.1

     

     

     

    442.3

     

     

     

    443.4

     

     

     

     

     

     

     

     

     

    Operating cash flow conversion

     

    159

    %

     

     

    172

    %

     

     

    133

    %

     

     

    130

    %

    Free cash flow conversion

     

    123

    %

     

     

    133

    %

     

     

    97

    %

     

     

    101

    %

    Table 6: Reconciliation of Estimated 2025 Change in Net Sales to Change in Organic Sales

     

    Guidance(4)

     

    Full Year 2025

     

    Low End

     

    High End

    Estimated change in net sales

    5

    %

     

    6

    %

    Less:

     

     

     

    Net impact from acquisitions/divestitures(1)

    3

    %

     

    4

    %

    Impact from foreign currency(2)

    1

    %

     

    1

    %

    Estimated change in organic sales

    1

    %

     

    1

    %

    Table 7: Reconciliation of Estimated 2025 Diluted EPS Attributable to IDEX to Adjusted Diluted EPS Attributable to IDEX

     

    Guidance(4)

     

    Full Year 2025

    Estimated diluted EPS attributable to IDEX

    $6.35 - $6.40

    Fair value inventory step-up charges

    0.01

    Tax impact on fair value inventory step-up charges

    —

    Restructuring expenses and asset impairments(5)

    $0.25

    Tax impact on restructuring expenses and asset impairments

    $(0.06)

    Acquisition-related intangible asset amortization

    $1.72

    Tax impact on acquisition-related intangible asset amortization

    $(0.41)

    Estimated adjusted diluted EPS attributable to IDEX

    $7.86 - $7.91

    Table 8: Reconciliation of Estimated 2025 Net Income to Adjusted EBITDA (dollars in millions)

     

    Guidance(4)

     

    Full Year 2025

     

    Low End

     

    High End

    Estimated Reported net income

    $

    478.0

     

     

    $

    481.6

     

    Provision for income taxes

     

    150.7

     

     

     

    152.0

     

    Interest expense - net

     

    65.4

     

     

     

    65.4

     

    Depreciation

     

    76.7

     

     

     

    76.7

     

    Amortization of intangible assets

     

    130.6

     

     

     

    130.6

     

    Fair value inventory step-up charges

     

    0.6

     

     

     

    0.6

     

    Restructuring expenses and asset impairments(5)

     

    19.2

     

     

     

    19.2

     

    Estimated Adjusted EBITDA

    $

    921.2

     

     

    $

    926.1

     

     

     

     

     

    Estimated Net sales

    $

    3,445.3

     

     

    $

    3,461.3

     

     

     

     

     

    Estimated Net income margin

     

    13.9

    %

     

     

    13.9

    %

    Estimated Adjusted EBITDA margin

     

    26.5

    %

     

     

    27.0

    %

    (1)

    Represents the sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture.

     

     

    (2)

    The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales, and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period.

     

     

    (3)

    This adjustment represents the amount of Restructuring expenses and asset impairments attributable to IDEX. Restructuring expenses and asset impairments of $18.3 million on the Condensed Consolidated Statements of Income during the nine months ended September 30, 2025 included charges of $0.6 million recognized by the Company's joint venture, $0.3 million of which was attributable to noncontrolling interest.

     

     

    (4)

    Amounts may not foot or recalculate precisely due to rounding.

     

     

    (5)

    Represents estimated restructuring costs to be incurred during the remainder of 2025, primarily related to severance.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251029941980/en/

    Investor Contact:

    Jim Giannakouros, CFA

    Vice President, Investor Relations

    (847) 313-9506

    Get the next $IEX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IEX

    DatePrice TargetRatingAnalyst
    8/14/2024Buy → Hold
    Argus
    2/8/2024$215.00 → $265.00Hold → Buy
    Stifel
    10/5/2023$200.00Neutral
    Exane BNP Paribas
    7/18/2022$229.00 → $188.00Buy → Hold
    Stifel
    7/14/2022$215.00Perform → Outperform
    Oppenheimer
    3/9/2022Market Perform → Outperform
    Cowen & Co.
    3/9/2022$220.00Market Perform → Outperform
    Cowen
    1/11/2022$230.00Market Perform
    Bernstein
    More analyst ratings

    $IEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IDEX Reports Third Quarter Results

    Highlights (All comparisons are against the prior year period unless otherwise noted) Record sales of $879 million increased 10% on a reported basis and 5% organically Reported diluted EPS of $1.70 increased 8%, and adjusted diluted EPS of $2.03 increased 7% Record orders of $880 million increased 13% on a reported basis and 7% organically Narrowed full year EPS outlook GAAP diluted EPS of $6.35 - $6.40 Adjusted diluted EPS of $7.86 - $7.91 Utilized $75 million for share repurchases in Q3 2025 and $175 million year-to-date Increased share repurchase authorization to $1 billion IDEX Corporation (NYSE:IEX) today announced its financial results for the three-mont

    10/29/25 7:00:00 AM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Corporation to Webcast Third Quarter 2025 Earnings Call

    IDEX Corporation (NYSE:IEX) announced today that it will release its third quarter 2025 results on Wednesday, October 29, 2025, prior to market open. An investor conference call and webcast will take place at 8:00 a.m. (CT) that same day with Chief Executive Officer and President Eric Ashleman and Vice President Corporate Development and Interim Chief Financial Officer Akhil Mahendra. The event and associated earnings presentation will be available via webcast in listen-only mode on the Company's Investor Relations site at https://investors.idexcorp.com/events. To participate via telephone, please dial (877) 709-8150 or (201) 689-8354 and use confirmation code 13748413. Telephone particip

    10/10/25 2:53:00 PM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Corporation Announces Increase to Share Repurchase Authorization and Declares Regular Quarterly Cash Dividend

    IDEX Corporation (NYSE:IEX) announced today that its Board of Directors has increased the Company's share repurchase authorization, bringing total repurchase capacity to $1 billion from approximately $440 million remaining as of June 30, 2025. "This announcement highlights the confidence we have in our growth strategy and underscores our proven ability to consistently generate strong free cash flow. For the full year 2025, we expect to return at least 70% of free cash flow to shareholders through dividends and share repurchases. We plan to take a dynamic approach to capital allocation as we invest in growth opportunities that position IDEX for continued value creation and success," said E

    9/18/25 4:52:00 PM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Christenson Carl R bought $101,647 worth of shares (600 units at $169.41), increasing direct ownership by 10% to 6,351 units (SEC Form 4)

    4 - IDEX CORP /DE/ (0000832101) (Issuer)

    11/7/25 4:50:06 PM ET
    $IEX
    Fluid Controls
    Industrials

    Director Helmkamp Katrina L bought $399,026 worth of shares (2,500 units at $159.61), increasing direct ownership by 23% to 13,200 units (SEC Form 4)

    4 - IDEX CORP /DE/ (0000832101) (Issuer)

    8/11/25 4:22:26 PM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    IDEX Corp downgraded by Argus

    Argus downgraded IDEX Corp from Buy to Hold

    8/14/24 7:53:05 AM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Corp upgraded by Stifel with a new price target

    Stifel upgraded IDEX Corp from Hold to Buy and set a new price target of $265.00 from $215.00 previously

    2/8/24 6:32:52 AM ET
    $IEX
    Fluid Controls
    Industrials

    Exane BNP Paribas initiated coverage on IDEX Corp with a new price target

    Exane BNP Paribas initiated coverage of IDEX Corp with a rating of Neutral and set a new price target of $200.00

    10/5/23 7:37:30 AM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Christenson Carl R bought $101,647 worth of shares (600 units at $169.41), increasing direct ownership by 10% to 6,351 units (SEC Form 4)

    4 - IDEX CORP /DE/ (0000832101) (Issuer)

    11/7/25 4:50:06 PM ET
    $IEX
    Fluid Controls
    Industrials

    Director Helmkamp Katrina L bought $399,026 worth of shares (2,500 units at $159.61), increasing direct ownership by 23% to 13,200 units (SEC Form 4)

    4 - IDEX CORP /DE/ (0000832101) (Issuer)

    8/11/25 4:22:26 PM ET
    $IEX
    Fluid Controls
    Industrials

    Interim CFO Mahendra Akhil sold $45,222 worth of shares (250 units at $180.89), decreasing direct ownership by 5% to 5,035 units (SEC Form 4)

    4 - IDEX CORP /DE/ (0000832101) (Issuer)

    6/9/25 4:26:03 PM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    SEC Filings

    View All

    SEC Form 10-Q filed by IDEX Corporation

    10-Q - IDEX CORP /DE/ (0000832101) (Filer)

    10/29/25 3:47:05 PM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IDEX CORP /DE/ (0000832101) (Filer)

    10/29/25 7:08:27 AM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - IDEX CORP /DE/ (0000832101) (Filer)

    9/18/25 4:58:30 PM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Leadership Updates

    Live Leadership Updates

    View All

    Littelfuse Names Abhi Khandelwal Chief Financial Officer

    Littelfuse, Inc. (NASDAQ:LFUS), a leader in developing smart solutions that enable safe and efficient electrical energy transfer, today announced that Abhi Khandelwal has been appointed Executive Vice President and Chief Financial Officer, effective June 18, 2025. Mr. Khandelwal brings more than 20 years of financial and operational experience to Littelfuse, most recently serving as Executive Vice President and Chief Financial Officer at IDEX Corporation (NYSE:IEX). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527700889/en/Abhi Khandelwal, Chief Financial Officer Dr. Greg Henderson, Littelfuse President & Chief Executive Of

    5/27/25 7:00:00 AM ET
    $IEX
    $LFUS
    $CIR
    Fluid Controls
    Industrials
    Electrical Products
    Energy

    IDEX Corporation Appoints Stephanie Disher and Matthijs Glastra to Board of Directors; David Parry and Livingston Satterthwaite to Retire

    IDEX Corporation (NYSE:IEX) today announced the appointment of Stephanie ("Steph") Disher and Matthijs Glastra to the company's Board of Directors. The appointments, effective Friday, February 21, 2025, increase the size of the Board from 10 to 12 directors. Ms. Disher will serve on the Board's Nominating and Corporate Governance Committee, and Mr. Glastra will serve on the Board's Audit Committee. Ms. Disher currently serves as Chief Executive Officer of Atmus Filtration Technologies Inc. (NYSE:ATMU), a leader in filtration and media solutions. She has extensive global leadership experience in finance and operations from her time at Atmus, Cummins Inc. and BP, p.l.c. Mr. Glastra currentl

    2/20/25 5:07:00 PM ET
    $ATMU
    $IEX
    $NOVT
    Auto Parts:O.E.M.
    Consumer Discretionary
    Fluid Controls
    Industrials

    Amprius Appoints Transportation Industry Veteran Tony Satterthwaite to Board of Directors

    Mr. Satterthwaite Brings Over 30 Years of Global Power Generation Experience to Amprius Technologies Amprius Technologies, Inc. ("Amprius" or the "Company") (NYSE:AMPX), a leader in next-generation lithium-ion batteries with its Silicon Anode Platform, has appointed Livingston "Tony" Satterthwaite as an independent director on its Board of Directors (the "Board"), effective August 13, 2024. Mr. Satterthwaite will also be joining the Board's Compensation Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240814317462/en/Amprius Appoints Transportation Industry Veteran Tony Satterthwaite to Board of Directors (Photo: Busi

    8/14/24 5:00:00 PM ET
    $AMPX
    $CC
    $IEX
    Industrial Machinery/Components
    Miscellaneous
    Major Chemicals
    Industrials

    $IEX
    Financials

    Live finance-specific insights

    View All

    IDEX Reports Third Quarter Results

    Highlights (All comparisons are against the prior year period unless otherwise noted) Record sales of $879 million increased 10% on a reported basis and 5% organically Reported diluted EPS of $1.70 increased 8%, and adjusted diluted EPS of $2.03 increased 7% Record orders of $880 million increased 13% on a reported basis and 7% organically Narrowed full year EPS outlook GAAP diluted EPS of $6.35 - $6.40 Adjusted diluted EPS of $7.86 - $7.91 Utilized $75 million for share repurchases in Q3 2025 and $175 million year-to-date Increased share repurchase authorization to $1 billion IDEX Corporation (NYSE:IEX) today announced its financial results for the three-mont

    10/29/25 7:00:00 AM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Corporation to Webcast Third Quarter 2025 Earnings Call

    IDEX Corporation (NYSE:IEX) announced today that it will release its third quarter 2025 results on Wednesday, October 29, 2025, prior to market open. An investor conference call and webcast will take place at 8:00 a.m. (CT) that same day with Chief Executive Officer and President Eric Ashleman and Vice President Corporate Development and Interim Chief Financial Officer Akhil Mahendra. The event and associated earnings presentation will be available via webcast in listen-only mode on the Company's Investor Relations site at https://investors.idexcorp.com/events. To participate via telephone, please dial (877) 709-8150 or (201) 689-8354 and use confirmation code 13748413. Telephone particip

    10/10/25 2:53:00 PM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Corporation Announces Increase to Share Repurchase Authorization and Declares Regular Quarterly Cash Dividend

    IDEX Corporation (NYSE:IEX) announced today that its Board of Directors has increased the Company's share repurchase authorization, bringing total repurchase capacity to $1 billion from approximately $440 million remaining as of June 30, 2025. "This announcement highlights the confidence we have in our growth strategy and underscores our proven ability to consistently generate strong free cash flow. For the full year 2025, we expect to return at least 70% of free cash flow to shareholders through dividends and share repurchases. We plan to take a dynamic approach to capital allocation as we invest in growth opportunities that position IDEX for continued value creation and success," said E

    9/18/25 4:52:00 PM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IDEX Corporation

    SC 13G/A - IDEX CORP /DE/ (0000832101) (Subject)

    10/7/24 1:03:55 PM ET
    $IEX
    Fluid Controls
    Industrials

    SEC Form SC 13G/A filed by IDEX Corporation (Amendment)

    SC 13G/A - IDEX CORP /DE/ (0000832101) (Subject)

    2/13/24 5:06:23 PM ET
    $IEX
    Fluid Controls
    Industrials

    SEC Form SC 13G/A filed by IDEX Corporation (Amendment)

    SC 13G/A - IDEX CORP /DE/ (0000832101) (Subject)

    2/12/24 10:07:40 AM ET
    $IEX
    Fluid Controls
    Industrials